|
Study examines drug regimen for the treatment of non-small cell lung cancer …
Science Codex WASHINGTON, DC – Analysis of a drug regimen approved by the FDA in 2006 for the treatment of non-small cell lung cancer (bevacizumab added to the standard chemotherapy regimen carboplatin and paclitaxel) finds Medicare insured patients age 65 years and … Adding Drug to Standard Chemotherapy Provides No Survival Benefit for Older … Bevacizumab Doesn't Prolong Lung Cancer Survival in Elderly Avastin for Lung Cancer |
View full post on lung cancer – Google News
